We are delighted to announce that additional Series B funding has been agreed, with the members of Italian Angels for Growth and Club degli Investitori having committed funds of £0.6m ($1m). This financing will be used to further advance the candidates in NeoPhore’s drug discovery pipeline.
11.10.2021
Additional Series B funding announcement
More news
21.04.2026
AACR 2026 and AACR Cancer Discovery Article
NeoPhore Press Release: AACR 2026 and AACR Cancer Discovery Article London UK, 21 April 2026 NeoPhore, an immuno-oncology company, announces the …
16.09.2025
NeoPhore's CEO Presents at Morgan Stanley 23rd Annual Global Healthcare Conference | September 2025
NeoPhore's CEO - Michael Shih - recently presented the NeoPhore story at the Morgan Stanley Global Healthcare Conference on Monday September 8th …
16.12.2024
NeoPhore appoints Michael Shih as Chief Executive Officer
NeoPhore appoints Michael Shih as Chief Executive Officer Highly experienced corporate development leader with a track record of international pharma …